Target intelligence / Profile preview

Bundibugyo Virus Envelope Glycoprotein (GP)

Target: GP
Molecular classification: Viral protein, Glycoprotein, Fusion protein

Overview

The Bundibugyo virus glycoprotein (GP) is the envelope protein of the Bundibugyo ebolavirus. It is a trimeric complex of GP1 and GP2 subunits. GP1 mediates attachment to host cell receptors, while GP2 facilitates membrane fusion. The GP is heavily glycosylated, shielding it from immune recognition and presenting a challenge for therapeutic intervention.

Mechanism of action

Viral entry inhibition

Biological functions

Viral entryReceptor bindingMembrane fusion

Disease associations

InfectionEbola virus disease

Safety considerations

Immune evasion due to glycosylationStructural complexity hindering drug development

Beyond the preview

Go deeper on Bundibugyo Virus Envelope Glycoprotein (GP).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bundibugyo Virus Envelope Glycoprotein (GP).

Explore the full profile